Since anti-IFNβ autoAbs are relatively rare (Bastard et al., 2020; Fernbach et al., 2024), patients harboring anti-IFNα or anti-IFNω autoAbs and suffering from severe viral infections have been treated with IFNβ in early trials to explore whether the negative effects of anti-IFNα/ω autoAbs could be bypassed (Bastard et al., 2021b). Here, IFNB1 is linked to viral infectious disease.